1. Home
  2. SSP vs WHWK Comparison

SSP vs WHWK Comparison

Compare SSP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$2.75

Market Cap

264.6M

Sector

Industrials

ML Signal

HOLD

WHWK

Whitehawk Therapeutics Inc.

HOLD

Current Price

$4.33

Market Cap

233.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSP
WHWK
Founded
1878
2007
Country
United States
United States
Employees
N/A
23
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.6M
233.4M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
SSP
WHWK
Price
$2.75
$4.33
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$6.95
$7.50
AVG Volume (30 Days)
574.7K
277.9K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,150,585,000.00
N/A
Revenue This Year
$8.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$1.57
52 Week High
$5.39
$5.50

Technical Indicators

Market Signals
Indicator
SSP
WHWK
Relative Strength Index (RSI) 29.81 52.37
Support Level $2.73 $3.80
Resistance Level $3.01 $4.38
Average True Range (ATR) 0.21 0.28
MACD -0.04 -0.02
Stochastic Oscillator 21.37 43.45

Price Performance

Historical Comparison
SSP
WHWK

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

Share on Social Networks: